Human Recombinant IGFBP-4, STEMCELL Technologies (CAT#: STEM-CT-0891-ZJF)

Insulin-like growth factor-binding protein 4 (IGFBP-4) inhibits the actions of IGF-I and IGF-II. The distribution of IGFBP-4 in tissues is dependent on its glycosylation state, however it preferentially targets connective tissue (Firth & Baxter; Qin et al.). IGFBP-4 is also produced in liver, adrenal glands, Leydig cells, developing embryos, spinal cord, and thymic cortex. IGFBP-4 inhibits WNT/β-catenin signaling, which downregulates prostate cancer proliferation (Zhu et al.). In vitro studies suggest that IGFBP-4 inhibits proliferation of neuroblastoma and glioma, while promoting bone loss in osteosarcoma and multiple myeloma (Durai et al.).

Subtype: Cytokines, Growth Factors
Cell Type: Mesenchymal Stem and Progenitor Cells
Species: Human
Area of Interest: Stem Cell Biology
Purity: ≥ 95%

Reliable Consistency: Guarantees uniformity and repeatability in various applications with endotoxin levels below 0.2 EU/μg.
Free of Animal Components: Completely devoid of any animal or human-derived elements.
Broad Selection: Offers a wide range of human, mouse, and rat cytokines available in multiple sizes.

Human Recombinant IGF-I, ACF, STEMCELL Technologies
Human Recombinant IGF-II, STEMCELL Technologies
Human Recombinant IHH, STEMCELL Technologies
Human Recombinant IL-1 alpha, STEMCELL Technologies